Midsummer is considered prime beach season, but investors know that, more importantly, it's second-quarter earnings season.
With that in mind, this episode of The Motley Fool's Market Checkup is dedicated to heavy hitters in the pharmaceutical industry. Watch and find out how the second-quarter results of four Big Pharma stocks stack up, and what challenges and opportunities lie ahead for them.
In this video, health-care analysts David Williamson and Max Macaluso drill down on Eli Lilly's recent results, detailing everything investors need to know, including whether the company's strong performance can continue into the future.
Still in the dark about how Obamacare might affect you and your portfolio? Don't worry -- you're not alone. To help prepare investors for the massive changes coming to the American health-care system, The Motley Fool created a special free report that makes this complex topic easily understandable. Download "Everything You Need to Know About Obamacare" and discover how the law may affect your taxes, health insurance, and investments. Click here for your free copy today.
The article Eli Lilly's Earnings Made Easy originally appeared on Fool.com.
David Williamson owns shares of Pfizer, Merck, and Eli Lilly. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.